FDA Accepts ANDA for Tolvaptan by Alkem Labs
The FDA has accepted the Abbreviated New Drug Application (ANDA) for Tolvaptan submitted by Alkem Labs.
Therapeutic Area
Therapeutic area intelligence for Vasopressin Antagonist with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.